CN104001102A - Traditional Chinese medicine combination for treating children otitis media and medical application thereof - Google Patents
Traditional Chinese medicine combination for treating children otitis media and medical application thereof Download PDFInfo
- Publication number
- CN104001102A CN104001102A CN201410275200.8A CN201410275200A CN104001102A CN 104001102 A CN104001102 A CN 104001102A CN 201410275200 A CN201410275200 A CN 201410275200A CN 104001102 A CN104001102 A CN 104001102A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- radix
- otitis media
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the medical technical field and relates to a traditional Chinese medicine combination for treating children otitis media and the medical application thereof. The medicine is made from indigo naturalis, fossilizid, dandelion, coptis chinensis, dried alum, rheum officinale, borneol, dragon's blood, honeysuckle, bighead atractylodes rhizome, amomum, north china iris roots, radix angelicae, codonopsis pilosula, gallnut, hypericum japonicum, pomelo leaves and common andrographis herb. The traditional Chinese medicine combination is remarkable in anti-inflammatory and analgesic activity, remarkable in curative effect, safe, reliable, and broad in clinical application prospects.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of Chinese medicine composition and medical usage thereof for the treatment of otitis media.
Background technology
Otitis media is modal a kind of disease, is mainly divided into apyetous and suppurative two large classes, cardinal symptom be suppurate, tinnitus and ear pain.Otitis media has multiple different pathogeny and symptom, and wherein acute and chronic catarrhal otitis media belongs to non-suppurative otitis media, and its symptom is: auditory dysesthesia, has deafness, tinnitus, in ear has current innervation while certainly listening enhancing, head movement.Instrument inspection is visible, otopiesis, and incorrect marking is clear, and limitation of activity has pharyngeal bone vessel dysfunction.Common cold, throat infection all can cause this disease, acutely easily controls chronic cannot radical cure.The conventional treatments of otitis media is exactly drug administration, and the traditional Chinese medical science thinks that kidney governing bones marrow has one's ideas straightened out in ear, should be main from yin nourishing removing heat from the heart to restore the consciousness, with dispelling wind and heat pathogens, and heat-clearing and detoxifying herb, with therapy of combining Chinese and Western medicine, effect is better.
At present, the otitis media Western medicine for the treatment of is a lot, but most drug therapeutic effect is poor, and treats in addition the shortcomings such as high, side effect is large, even affects patient health when serious.In addition, also have the Chinese medicine of a lot for the treatment of otitis media, but the shortcoming such as great majority have that therapeutic effect is poor, cure rate is low and treatment cycle is long.
Summary of the invention
In order to make up the deficiencies in the prior art, alleviate otitis media patient's misery, the invention provides a kind of Chinese medicine composition for the treatment of infantile tympanitis, it is evident in efficacy, safe and reliable, has wide potential applicability in clinical practice.
Technical scheme of the present invention is:
Treat a Chinese medicine composition for infantile tympanitis, this Chinese medicine composition is made up of the raw material of following weight portion: Indigo Naturalis 10-12 part, Os Draconis 5-8 part, Herba Taraxaci 6-9 part, Rhizoma Coptidis 3-5 part, dried Alumen 10-12 part, Radix Et Rhizoma Rhei 10-12 part, MEIHUA BINGPIAN 3-5 part, Sanguis Draxonis 3-5 part, Flos Lonicerae 10-12 part, Rhizoma Atractylodis Macrocephalae 8-10 part, Fructus Amomi 6-9 part, Radix Iridis Chinensis 10-12 part, Radix Angelicae Dahuricae 10-12 part, Radix Codonopsis 10-12 part, Galla Chinensis 12-15 part, Herba Hyperici Japonici 9-12 part, Folium Citri grandis 5-8 part and Herba Andrographis 12-15 part.
The present invention has carried out preferably the parts by weight of above-mentioned all taste Chinese medicine, and preferred condition is the enhancing of medicine to otitis media therapeutic effect after each drug matching is used.As a preferred embodiment of the present invention, Chinese medicine composition of the present invention is mainly made by the raw material of following weight portion: 13 parts of 11 parts of Indigo Naturaliss, 7 parts of Os Draconis, 7 parts of Herba Taraxacis, 4 parts of Rhizoma Coptidis, 11 parts of dried Alumens, 11 parts of Radix Et Rhizoma Rhei, 4 parts of MEIHUA BINGPIAN, 4 parts of Sanguis Draxonis, 11 parts of Flos Loniceraes, 9 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts of Fructus Amomis, 11 parts of Radix Iridis Chinensiss, 11 parts of the Radixs Angelicae Dahuricae, 11 parts of Radix Codonopsis, 13 parts of Galla Chinensiss, 10 parts of Herba Hyperici Japonici, 7 parts of Folium Citri grandis and Herba Andrographis.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in preparation treatment otitis media medicine.Pharmaceutical composition of the present invention, in the time for the treatment of otitis media, demonstrates remarkable anti-inflammatory and antalgic activity.Drug effect embodiment 6 of the present invention shows, give positive drug and Chinese medicine composition of the present invention and all can obtain significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have utmost point significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group will significantly be better than positive controls.Drug effect embodiment 7 mices of the present invention lick foot response latency time showing, with model group comparison, after administration after 1h and 2h, the mice of each administration group of Chinese medicine composition of the present invention licks and is all greater than model group sufficient incubation period of reacting, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).Illustrate this Chinese medicine composition of the present invention can extend mice to hot plate stimulate lick the sufficient response latency, have certain analgesic activity.Under same experiment condition, positive control drug has also extended mice and has licked the incubation period that foot reacts, and has certain analgesic activity, but its analgesic effect and model group there was no significant difference.
In order to express better Chinese medicine composition of the present invention, Chinese medicine composition of the present invention can be prepared into conventional clinically dosage form.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule, described pharmaceutical preparation all can prepare according to Chinese medicine preparation preparation method well-known to those skilled in the art.Preferably, Chinese medicine composition of the present invention is prepared into powder, water preparation, tablet or capsule according to conventional preparation technology.
The present invention also provides a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, doubly adding volumetric concentration according to the 4-9 of coarse powder gross weight is the alcoholic solution of 40%-95%, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule etc.
The present invention is that inventor is through research repeatedly, progressively improve, last successful a kind of curative effect is treated the medicine of otitis media preferably, for showing the therapeutic effect of medicine of the present invention to otitis media, the otitis media patient that the present invention takes this medicine to 120 examples has carried out clinical observation, and otitis media patient's 120 examples of selecting to have a comparability as a control group.Treatment group patient takes medicine twice of the present invention every day, sooner or later respectively once, once takes 5 grams of medicines, and matched group patient takes the oral drugs of conventional therapy otitis media.Treat after one month, therapeutic outcome is in table 1.
Table 1 treatment group and treatment of control group result synopsis
Treatment group is compared matched group and is had higher cure rate and effective percentage, thinks thus, and Drug therapy otitis media of the present invention has good effect, and observes through the treatment of month, takes medicine of the present invention and does not occur any toxic and side effects.
Chinese medicine composition of the present invention, aspect treatment otitis media, compared with prior art has following advantage:
1) compared with the chemotherapeutic agent of current treatment, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, and untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, and has improved patient's quality of life;
2) in Chinese medicine composition of the present invention, contain multi-medicament component, action target spot is numerous, compared with positive control drug, pharmaceutical composition Chinese medicine composition of the present invention is more remarkable at antiinflammatory and ease pain, show that the present composition has significant synergism in treating otitis media, not only can significantly improve the symptom of otitis media, can also delay the development of otitis media, the recovery from illness process that contributes to otitis media patient, has wide potential applicability in clinical practice.
Detailed description of the invention
Further describe the present invention by specific embodiment below, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, change, combination or replacement that the present invention is carried out, be apparent for a person skilled in the art, and be included within the scope of the present invention.
one) example of formulations part
embodiment 1 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 12 parts of 10 parts of Indigo Naturaliss, 5 parts of Os Draconis, 6 parts of Herba Taraxacis, 3 parts of Rhizoma Coptidis, 10 parts of dried Alumens, 10 parts of Radix Et Rhizoma Rhei, 3 parts of MEIHUA BINGPIAN, 3 parts of Resina Draconis, 10 parts of Flos Loniceraes, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts of Fructus Amomis, 10 parts of Radix Iridis Chinensiss, 10 parts of the Radixs Angelicae Dahuricae, 10 parts of Radix Codonopsis, 12 parts of Galla Chinensiss, 9 parts of Herba Hyperici Japonici, 5 parts of Folium Citri grandis and Herba Andrographis.
Get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, doubly adding volumetric concentration according to the 4-9 of coarse powder gross weight is the alcoholic solution of 40%-95%, reflux, extract, three times, return time is 2-5h, filters filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule etc.
embodiment 2 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 15 parts of 12 parts of Indigo Naturaliss, 8 parts of Os Draconis, 9 parts of Herba Taraxacis, 5 parts of Rhizoma Coptidis, 12 parts of dried Alumens, 12 parts of Radix Et Rhizoma Rhei, 5 parts of MEIHUA BINGPIAN, 5 parts of Sanguis Draxonis, 12 parts of Flos Loniceraes, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 9 parts of Fructus Amomis, 12 parts of Radix Iridis Chinensiss, 12 parts of the Radixs Angelicae Dahuricae, 12 parts of Radix Codonopsis, 15 parts of Galla Chinensiss, 12 parts of Herba Hyperici Japonici, 8 parts of Folium Citri grandis and Herba Andrographis.
Preparation method is with embodiment 1.
embodiment 3 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 13 parts of 11 parts of Indigo Naturaliss, 7 parts of Os Draconis, 7 parts of Herba Taraxacis, 4 parts of Rhizoma Coptidis, 11 parts of dried Alumens, 11 parts of Radix Et Rhizoma Rhei, 4 parts of MEIHUA BINGPIAN, 4 parts of Sanguis Draxonis, 11 parts of Flos Loniceraes, 9 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts of Fructus Amomis, 11 parts of Radix Iridis Chinensiss, 11 parts of the Radixs Angelicae Dahuricae, 11 parts of Radix Codonopsis, 13 parts of Galla Chinensiss, 10 parts of Herba Hyperici Japonici, 7 parts of Folium Citri grandis and Herba Andrographis.
Preparation method is with embodiment 1.
embodiment 4 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 12 parts of 10 parts of Indigo Naturaliss, 5 parts of Os Draconis, 9 parts of Herba Taraxacis, 3 parts of Rhizoma Coptidis, 12 parts of dried Alumens, 12 parts of Radix Et Rhizoma Rhei, 5 parts of MEIHUA BINGPIAN, 3 parts of Resina Draconis, 10 parts of Flos Loniceraes, 8 parts of the Rhizoma Atractylodis Macrocephalaes, 9 parts of Fructus Amomis, 10 parts of Radix Iridis Chinensiss, 12 parts of the Radixs Angelicae Dahuricae, 10 parts of Radix Codonopsis, 15 parts of Galla Chinensiss, 9 parts of Herba Hyperici Japonici, 8 parts of Folium Citri grandis and Herba Andrographis.
Preparation method is with embodiment 1.
embodiment 5 Chinese medicine composition of the present invention and preparation technology
The weight portion of Chinese medicinal components: 15 parts of 12 parts of Indigo Naturaliss, 8 parts of Os Draconis, 6 parts of Herba Taraxacis, 5 parts of Rhizoma Coptidis, 10 parts of dried Alumens, 10 parts of Radix Et Rhizoma Rhei, 3 parts of MEIHUA BINGPIAN, 5 parts of Sanguis Draxonis, 12 parts of Flos Loniceraes, 10 parts of the Rhizoma Atractylodis Macrocephalaes, 6 parts of Fructus Amomis, 12 parts of Radix Iridis Chinensiss, 10 parts of the Radixs Angelicae Dahuricae, 12 parts of Radix Codonopsis, 12 parts of Galla Chinensiss, 12 parts of Herba Hyperici Japonici, 5 parts of Folium Citri grandis and Herba Andrographis.
Preparation method is with embodiment 1.
(2) drug effect embodiment part
the antiinflammatory action of embodiment 6 Chinese medicine composition xylol of the present invention induced mice inflammatory model
Hydrocortisone has stronger anti-inflammatory activity, that synthetic is also naturally occurring glucocorticoid, hydrocortisone enters after cell, activate cytoplasmic receptor, after allosteric, enter nucleus, be combined with DNA response element, cause inhibition or the induction of genetic transcription, the expression of inflammation associated protein is changed.
, experimental technique:
60 KM mices, male and female half and half, body weight 25-30 gram, be divided at random five groups by body weight, i.e. dosage group in model control group, combination group high dose group, compositions, compositions low dose group, positive controls, every group 12, each administration group mice gives respectively following medicine:
Model control group: gavage gives the normal saline of same volume;
Positive controls: gavage gives the hydrocortisone drug solution of 5mg/kg;
Compositions high dose group: gavage gives 50mg/kg embodiment 3 Chinese medicine composition Chinese medicine compositions by crude drug amount;
Dosage group in compositions: gavage gives 20 mg/kg embodiment 3 Chinese medicine compositions, and Chinese medicine composition is by crude drug amount;
Compositions low dose group: gavage gives 5 mg/kg embodiment 3 Chinese medicine compositions, and Chinese medicine composition is by crude drug amount;
Each administration group is administered once every day, successive administration 7d.After last administration, get dimethylbenzene 20 μ l, be applied to each mouse right ear.After 30 minutes, get and be respectively subject to reagent 0.03 ml to be evenly applied to respectively mouse right ear, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures the each group of mice left and right ear method of double differences.Ear method of double differences assay method: place cuts two ears along auricle baseline, lays auricle with 8mm card punch at the same position of left and right ear, weighs, and the ear method of double differences=auris dextra sheet weight-left auricle weight.The ear method of double differences can be used as evaluates antiinflammatory index.
, experimental result:
Measure each experimental mice ear method of double differences and evaluate the antiphlogistic effects of each medication group medicine.Measurement result is in table 1.
The comparison of the each experimental mice ear of table 1 method of double differences
With model control group comparison,
* p< 0.05; With model control group comparison,
* p< 0.01;
With positive controls comparison,
# p< 0.05; With positive controls comparison,
## p< 0.01.
Result demonstration gives positive drug and Chinese medicine composition of the present invention all can be obtained significant antiphlogistic effects, wherein the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and positive controls have utmost point significant difference, Chinese medicine composition low dose group and positive controls have significant difference, and this shows that the high dose group of Chinese medicine composition of the present invention and the antiphlogistic effects of low dose group will significantly be better than positive controls.
the impact of embodiment 7 Chinese medicine composition of the present invention on mice hot-plate analgesia
1 mice hot plate pain model is made
Body weight 20g left and right female mice is placed on hot plate dolorimeter, screen 80 of qualified ♀ mices and (lick metapedes time < 5 s or > 30 s throw aside, scald for preventing foot, also should establish deadline, be generally 60s), the incubation period of licking metapedes reaction taking mice is as threshold of pain index, get 50 jennies, be divided into 5 groups, 10/group, it is model group, hydrocortisone group, Chinese medicine composition of the present invention (making by Chinese medicine composition prescription and preparation technology described in embodiment 3) low dose group, middle dosage group and high dose group.Each group is gastric infusion, and 1 times/day, dosage is as shown in table 2, and after successive administration 14d, after mensuration last medicine, 60 min, 120 min lick the time of foot reaction.
2 Chinese medicine compositions of the present invention are on licking the impact of foot response latency in the experiment of mice hot-plate analgesia
Mice licks foot response latency time showing, with model group comparison, after administration, after 1h and 2h, the mice of each administration group of Chinese medicine composition of the present invention licks and is all greater than model group sufficient incubation period of reacting, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).Illustrate this Chinese medicine composition of the present invention can extend mice to hot plate stimulate lick the sufficient response latency, have certain analgesic activity.Under same experiment condition, positive control drug hydrocortisone group has also extended mice and has licked the incubation period that foot reacts, and has certain analgesic activity, but its analgesic effect and model group there was no significant difference.The results are shown in Table 2.
Table 2 mice lick foot response latency timetable (
)
Note: with model group comparison, *
p< 0.05, * *
p< 0.01.
Claims (5)
1. treat a Chinese medicine composition for infantile tympanitis, it is characterized in that being made by the raw material of following weight portion: Indigo Naturalis 10-12 part, Os Draconis 5-8 part, Herba Taraxaci 6-9 part, Rhizoma Coptidis 3-5 part, dried Alumen 10-12 part, Radix Et Rhizoma Rhei 10-12 part, MEIHUA BINGPIAN 3-5 part, Sanguis Draxonis 3-5 part, Flos Lonicerae 10-12 part, Rhizoma Atractylodis Macrocephalae 8-10 part, Fructus Amomi 6-9 part, Radix Iridis Chinensis 10-12 part, Radix Angelicae Dahuricae 10-12 part, Radix Codonopsis 10-12 part, Galla Chinensis 12-15 part, Herba Hyperici Japonici 9-12 part, Folium Citri grandis 5-8 part and Herba Andrographis 12-15 part.
2. the Chinese medicine composition for the treatment of infantile tympanitis as claimed in claim 1, is characterized in that being made up of the raw material of following weight portion: 13 parts of 11 parts of Indigo Naturaliss, 7 parts of Os Draconis, 7 parts of Herba Taraxacis, 4 parts of Rhizoma Coptidis, 11 parts of dried Alumens, 11 parts of Radix Et Rhizoma Rhei, 4 parts of MEIHUA BINGPIAN, 4 parts of Sanguis Draxonis, 11 parts of Flos Loniceraes, 9 parts of the Rhizoma Atractylodis Macrocephalaes, 8 parts of Fructus Amomis, 11 parts of Radix Iridis Chinensiss, 11 parts of the Radixs Angelicae Dahuricae, 11 parts of Radix Codonopsis, 13 parts of Galla Chinensiss, 10 parts of Herba Hyperici Japonici, 7 parts of Folium Citri grandis and Herba Andrographis.
3. the Chinese medicine composition for the treatment of infantile tympanitis as claimed in claim 1 or 2, is characterized in that: described Chinese medicine composition is powder, water preparation, tablet or capsule.
4. the Chinese medicine composition for the treatment of infantile tympanitis as claimed in claim 1 or 2, it is characterized in that its preparation method comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, doubly adding volumetric concentration according to the 4-9 of coarse powder gross weight is the alcoholic solution of 40%-95%, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule.
5. the purposes of the Chinese medicine composition described in claim 1 or 2 in preparation treatment otitis media medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410275200.8A CN104001102A (en) | 2014-06-19 | 2014-06-19 | Traditional Chinese medicine combination for treating children otitis media and medical application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410275200.8A CN104001102A (en) | 2014-06-19 | 2014-06-19 | Traditional Chinese medicine combination for treating children otitis media and medical application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104001102A true CN104001102A (en) | 2014-08-27 |
Family
ID=51362190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410275200.8A Pending CN104001102A (en) | 2014-06-19 | 2014-06-19 | Traditional Chinese medicine combination for treating children otitis media and medical application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104001102A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102743490A (en) * | 2012-07-14 | 2012-10-24 | 尤秀真 | Chinese medicament for treating acute otitis media |
| CN103585545A (en) * | 2013-11-16 | 2014-02-19 | 崔新明 | Traditional Chinese medicine composition for treating otitis media |
-
2014
- 2014-06-19 CN CN201410275200.8A patent/CN104001102A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102743490A (en) * | 2012-07-14 | 2012-10-24 | 尤秀真 | Chinese medicament for treating acute otitis media |
| CN103585545A (en) * | 2013-11-16 | 2014-02-19 | 崔新明 | Traditional Chinese medicine composition for treating otitis media |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103386008B (en) | Chinese medicine composition for treating endocrine dyscrasia | |
| CN102631579B (en) | Oral Chinese herbal preparation for treating post-traumatic brain syndrome | |
| CN104056177A (en) | Traditional Chinese medicine composition for treating otitis media | |
| Lin et al. | Herb pairs containing Curcumae Rhizoma (Ezhu): A review of bio-active constituents, compatibility effects and t-copula function analysis | |
| CN104027684A (en) | Traditional Chinese medicinal composition for treating gout and preparation method thereof | |
| CN103585545B (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN102335373A (en) | Chinese medicinal composition for treating upper respiratory tract infection, and preparation method thereof | |
| CN104435567A (en) | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout | |
| CN101926903A (en) | Chinese medicine preparation for curing facial paralysis | |
| CN104337989A (en) | Traditional Chinese medicine composition containing centipeda minima and frankincense for treating gout | |
| CN104623376B (en) | Be used for the treatment of prosopalgic medicine | |
| CN103041320B (en) | Traditional Chinese medicine composition for treating cervical spondylosis and preparation method thereof | |
| CN105982906A (en) | Application of 20(R)-ginsenoside Rg3 in preparing medicines or health products capable of alleviating or/and treating rheumatoid diseases and medicines | |
| CN101357185A (en) | Dentalgia inflammation-reliving medicine and preparation method thereof | |
| CN104001102A (en) | Traditional Chinese medicine combination for treating children otitis media and medical application thereof | |
| CN104324212A (en) | Traditional Chinese medicine composition for treating otitis media combined tinnitus and medical application thereof | |
| CN103316291A (en) | Anti acne of traditional Chinese medicine | |
| CN103751239B (en) | A kind of preparation method and applications of Radix Et Caulis Acanthopanacis Senticosi total glucosides and manyprickle acanthopanax general glycosides formulation | |
| CN102631429A (en) | Medicinal composition for treating rheumatoid arthritis and preparation method thereof | |
| CN104435629B (en) | A kind of recurrent oral ulceration for the treatment of merges Chinese medicine of laryngopharynx swelling and pain and uses thereof | |
| CN104623256A (en) | Traditional Chinese medicine composition for treating nasosinusitis | |
| CN104998154A (en) | Traditional Chinese medicine compound treating cervical spondylosis and acute pharyngitis | |
| CN105362999A (en) | Traditional Chinese medicine preparation for preventing and treating infantile repeated cold and preparation method thereof | |
| CN104825691A (en) | Traditional Chinese medicine composition for treating duodenal ulcer and application of traditional Chinese medicine composition | |
| CN104587137A (en) | Traditional Chinese medicine composition for treating aseptic cervicoshoulder myofascitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140827 |